UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2016
ENTEST BIOMEDICAL, INC.
(Exact Name of Company as Specified in Charter)
| | | |
| | | |
| Nevada | 333-154989 | 26-3431263 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| 4700 Spring Street, St 304 |
| La Mesa California, 91942 |
| (Address of Principal Executive Offices, Zip Code) |
| 619 702 1404 |
| (Company’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
(a) On September 13, 2016 Seale and Beers, CPAs , the independent registered public accounting firm for Entest Biomedical, Inc. , informed the Company that Beers was in the process of being acquired by AMC Auditing. On September 21, 2016 the Board of Directors of Entest BioMedical, Inc. (the “Registrant” or the “Company”) approved of the dismissal of Seale and Beers, CPAs (“Beers”) as the Registrant’s independent registered public accounting firm.
Beers’ report of the Company’s financial statements for the fiscal years ended August 31, 2015 and August 31, 2014 did not contain any adverse opinion or disclaimer of opinion, nor was modified as to uncertainty, audit scope, or accounting principles. The audit reports prepared by Beers for the fiscal years ending August 31, 2015 and August 31, 2014 contained a paragraph with respect to the Company's ability to continue as a going concern.
During the Registrant's two most recent fiscal years and the subsequent interim periods thereto there were no disagreements with Beers, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Beers’ satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements.
The Company provided Beers with a copy of this disclosure set forth under this Item 4.01 and has requested Beers to furnish a letter addressed to the Securities & Exchange Commission stating whether or not Beers agrees with the above statements.
A copy of this letter from Beers is attached hereto as Exhibit 16.1.
(b) On September 21, 2016, the Board of Directors of the Registrant, acting as the Registrant's Audit Committee, approved the engagement of AMC Auditing as its independent auditor. On same date, September 21, 2016, the accounting firm of AMC Auditing was engaged as the Registrant's new independent registered public accounting firm.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit 16.1 Letter from Seale and Beers, CPAs
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ENTEST BIOMEDICAL, INC. |
| | |
| Dated: September 23, 2016 | By: /s/ David Koos |
| | David Koos |
| | Chief Executive Officer |
